SENATE CHAMBER STATE OF OKLAHOMA

DISPOSITION

FLOOR AMENDMENT		No	_	
COMMITTEE AMENDM	<u>IENT</u>			
				(Date)
Mr./Madame President:				
1.0	- P'II N - 044			
I move to amend Sena enacting clause and entire boo			ig the attached f	loor substitute for the title
			Submitted by:	
			Senator Standr	idge
Standridge-DC-FS-Req#3979 3/9/2020 12:06 PM				
(Floor Amendments Only)	Date and Time	e Filed:		
Untimely	Ameno	dment Cycle Ex	ctended	Secondary Amendment

1	STATE OF OKLAHOMA				
2	2nd Session of the 57th Legislature (2020)				
3	FLOOR SUBSTITUTE				
4	FOR SENATE BILL NO. 940 By: Standridge of the Senate				
5	and				
6	McEntire of the House				
7					
8					
9	FLOOR SUBSTITUTE				
10	[Prescription Drug Safety and Cost Reduction Importation Pilot Program Act - application -				
11	criteria for drugs - identification number - eligibility of pharmacies - fee - contract - reimbursement - prohibited acts - requirements - advisory council - codification - effective date -				
12					
13	emergency]				
14					
15					
16	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:				
17	SECTION 1. NEW LAW A new section of law to be codified				
18	in the Oklahoma Statutes as Section 3092 of Title 63, unless there				
19	is created a duplication in numbering, reads as follows:				
20	A. This section shall be known and may be cited as the				
21	"Prescription Drug Safety and Cost Reduction Importation Pilot				
22	Program Act".				
23	B. The Oklahoma Health Care Authority shall submit an				
24	application to the United States Secretary of Health and Human				

- Services for the purpose of establishing a prescription drug

 importation pilot program for the state Medicaid program to import

 pharmaceutical drugs from one or more countries approved by the

 United States Food and Drug Administration (FDA). The importation

 pilot program shall comply with the applicable requirements of 21

 U.S.C., Section 384 including, but not limited to, the requirements

 pertaining to safety and cost savings.
- C. The Authority shall identify the top twenty (20) most 8 9 frequently prescribed drugs through the state Medicaid program that 10 have a large cost differential between Canadian and United States 11 average prices whose importation will create significant cost 12 savings in the state Medicaid program. Not less than six (6) months following approval of the application described in subsection B of 13 this section, the Authority shall make available the top twenty (20) 14 highly prescribed drugs as provided in this paragraph to pharmacies 15 willing to participate. Prescription drugs identified: 16
 - Shall be legally importable under applicable federal and state law;
 - 2. Shall not include a controlled dangerous substance;
 - 3. Shall not include a biological product;

17

18

19

20

- 4. Shall not include an infused drug, including a peritoneal dialysis solution;
- 5. Shall not include marijuana, medical marijuana, cannabidiol or related derivatives;

6. Shall not include an intravenously injected drug; and

- 7. Shall be in compliance with applicable state and federal standards for safety and effectiveness.
- D. The Authority shall purchase drugs only from suppliers approved by FDA in countries approved by FDA. Except for drugs to which FDA issues a National Drug Code number, the Authority shall issue a unique identification number to each drug in the importation pilot program for the purposes of tracking and submitting claims to the Authority.
- E. Only a retail pharmacy located in this state that has a valid license issued by the State Board of Pharmacy may participate in the importation pilot program. The Authority shall create a simple application for applying pharmacies which shall include a field for the pharmacy's license number. The application shall be made available on the website of the Authority. Upon receipt of a completed application, the Authority shall verify the license with the Board and issue a permit to the pharmacy within thirty (30) calendar days authorizing the pharmacy to purchase drugs through the importation pilot program.
- F. The Authority shall establish a nominal fee-per-unit of imported pharmaceutical drugs, not to exceed three percent (3%) of the cost of the unit, to cover the costs of administration, warehousing and distribution in addition to the absolute cost of importation.

G. The Authority shall contract with the entity currently tasked with administering pharmacy benefits for the state Medicaid program on the effective date of this act for the purpose of administering the importation pilot program. A pharmacy benefit manager shall not be used for the importation pilot program.

- H. 1. A pharmacy participating in the importation pilot program shall submit claims to the Authority or the Authority's contracted third-party administrator, and shall be reimbursed through the state Medicaid program as provided in this subsection.
 - 2. The pharmacy shall be reimbursed in an amount equal to:
 - a. for a brand-name drug, the cost to the pharmacy of the drug, plus fifteen percent (15%), plus Fifteen Dollars (\$15.00), or
 - b. for a generic drug, the cost to the pharmacy of the drug, plus thirty percent (30%), plus Fifteen Dollars (\$15.00).
- 3. No pharmacy shall be reimbursed in an amount more or less than as provided in this subsection. If a pharmacy is reimbursed less than as provided in this subsection, the pharmacy shall, upon proof of purchase, be reimbursed the difference of the amount provided in this subsection and the amount of the actual reimbursement within thirty (30) days of an appeal and subsequent decision by the Authority in favor of the pharmacy. Any adjustments not reimbursed to the pharmacy within thirty (30) days of the

favorable decision shall be assessed interest with an annual percentage rate of twenty-five percent (25%) of the owed adjustment compounded daily until the payment is sent to the pharmacy. The accrued interest shall be paid to the pharmacy. No fees or other charges shall be assessed to a pharmacy in relation to the importation pilot program or any purchases executed pursuant to the importation pilot program.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- I. 1. A pharmaceutical manufacturer, supplier or any other entity shall not:
 - a. give or receive kickbacks or rebates, or participate in any other scheme that interferes with the transparency of the importation pilot program or interferes with pharmacies obtaining the lowest possible prices on drugs purchased through the importation pilot program,
 - b. take any action, by agreement, unilaterally or otherwise, that has the effect of fixing or otherwise controlling the price that a pharmaceutical supplier, distributor or dispenser charges or advertises from pharmaceuticals in the importation pilot program,
 - c. discriminate against a pharmaceutical supplier, distributor or dispenser based on whether the supplier, distributor or dispenser participates in the importation pilot program, or

d. manipulate the pharmaceutical market in this state or adversely affect consumer access to pharmaceuticals under the importation pilot program;

2. The Authority shall:

- ensure that savings are passed to consumers and not recouped or clawed back, retroactively or otherwise, by pharmaceutical manufacturers or any other entity,
- b. ensure that the importation pilot program complies with the requirements of 21 U.S.C, Section 360eee and 360eee-1, pertaining to the track and trace requirements in Title II of the Drug Security and Quality Act before imported prescription drugs come into possession of the wholesaler, and
- c. establish a process for seeking all appropriate federal approvals, waivers, exemptions or agreements, or a combination thereof, as needed to enable all covered entities enrolled in or eligible for the federal 340B Drug Pricing Program to participate in the importation pilot program to the fullest extent possible without jeopardizing eligibility in the 340B Program.
- J. Upon approval of the application described in subsection A of this section, the Authority shall form an advisory council that consists of key stakeholders including, but not limited to, consumer

```
and patient advocates, pharmacists, contracted providers under the
state Medicaid program and governmental agencies necessary to
propose rules and changes in law to enable the Authority to
implement the provisions of this section.
    K. Upon approval of the application described in subsection A
of this section, the Oklahoma Health Care Authority Board shall
promulgate rules to implement the provisions of this section.
    SECTION 2. This act shall become effective July 1, 2020.
   SECTION 3. It being immediately necessary for the preservation
of the public peace, health or safety, an emergency is hereby
declared to exist, by reason whereof this act shall take effect and
be in full force from and after its passage and approval.
    57-2-3979
                            3/9/2020 12:06:19 PM
                  DC
```

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24